Dr Reddy's halts semaglutide supplies on impurity issue
NiveshIQ
NSE: DRREDDY · Healthcare
Dr. Reddy's Laboratories Ltd.
₹1,342.00▼ ₹10.00 (-0.74%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on DRREDDY. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Dr. Reddy's Laboratories Ltd.
Dr. Reddy's Laboratories Limited is an integrated pharmaceutical company with operations in North America, Europe, India, Russia and other international markets. The core business is divided into Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others, with Global Generics producing prescription and OTC finished products, PSAI manufacturing active pharmaceutical ingredients and providing contract research, and Others focusing on oncology and inflammatory therapies. In FY24, the company generated ₹33,119 crore in revenue and ₹3,311 crore in net income, reflecting a 12% YoY revenue growth and a 9% increase in net profit. Recent developments include the DCGI approval of Zytorvi for advanced esophageal cancer, which is expected to boost the oncology pipeline and crea
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹28,011 Cr +13.54% | ₹32,644 Cr +16.54% | ₹33,700 Cr +3.24% |
| EBITDA Margin | 28.32% | 26.18% | 19.15% |
| Net Profit | ₹5,578 Cr +23.75% | ₹5,655 Cr +1.38% | ₹4,196 Cr -25.80% |
| EPS | ₹335.22 | ₹67.89 | ₹50.41 |
Annual figures in Indian Rupees (Crores). Source: company filings (NSE).
Recent News
Dr. Reddy's Laboratories Ltd. Share Price Live Today
Dr Reddy's Laboratories trades higher on the BSE
🔒
+ 3 more stories about Dr. Reddy's Laboratories Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q2FY27 results: revenue ₹8, 698 Cr, PAT ₹925 Cr, EPS ₹11.10, EBITDA margin 19.9%. Growth context: revenue YoY -1.5%, PAT YoY -31.3%, revenue QoQ +7.4%, PAT QoQ +108.1%.
Management highlights product launches, approvals, therapy‑mix improvement and order wins, along with a robust deal pipe...
FY26 (last completed FY): revenue ₹33, 700 Cr, PAT ₹4, 196 Cr, EBITDA margin 19.1%, EPS ₹50.41. Year-on-year: revenue Yo...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantMore Healthcare stocks
Everything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for DRREDDY
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track DRREDDY alongside your other holdings
Unlock full DRREDDY research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Dr. Reddy's Laboratories Ltd.?
NiveshIQ detects active intelligence signals for Dr. Reddy's Laboratories Ltd. (DRREDDY) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Dr. Reddy's Laboratories Ltd.?
Dr. Reddy's Laboratories Ltd. operates in the Healthcare sector with a market capitalisation of ₹9,545,347.9L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.